Skip to main content

Advertisement

Table 1 Baseline characteristics of patients sampled for lumefantrine pharmacokinetics.

From: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Variable Supervised arm Unsupervised arm
  < 5 years 5–14 years ≥15 years < 5 years 5–14 years ≥15 years
number sampled 70 92 79 68 91 79
sex ratio (M/F) 1.9 (46/24) 0.9 (43/49) 0.8 (36/43) 1.1 (36/32) 0.7 (37/54) 0.5 (28/51)
median age (range) 3 (1–4) 7 (5–14) 25 (15–60) 3 (1–4) 8 (5–14) 25 (15–80)
parasite density (median, IQR) 12 344 (4232–33 799) 15 668 (3750–36523) 6256 (1957–15 980) 22 777 (11 290–51 775) 11 367 (3449–32 475) 6156 (2749–19 459)
axillary temperature (°C) (mean, IQR) 37.5 (36.7–38.4) 37.3 (36.4–38.0) 36.7 (36.0–37.5) 37.7 (36.7–38.9) 37.1 (36.1–37.8) 36.7 (36.1–37.2)
weight-adjusted lumefantrine dose (mg/Kg) (mean, range) 66 (48–96) 72 (48–96) 53 (32–76) 68 (48–96) 73 (51–96) 54 (35–80)